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Abstract
Identifying the complete repertoire of genes and genetic variants that regulate the pathogenesis and
progression of human disease is a central goal of post-genomic biomedical research. In cancer,
recent studies have shown that genome-wide association studies can be successfully used to
identify germline polymorphisms associated with an individual's susceptibility to malignancy. In
parallel to these reports, substantial work has also shown that patterns of somatic alterations in
human tumors can be successfully employed to predict disease prognosis and treatment response.
A paper by Van Ness et al. published this month in BMC Medicine reports the initial results of a
multi-institutional consortium for multiple myeloma designed to evaluate the role of germline
polymorphisms in influencing multiple myeloma clinical outcome. Applying a custom-designed single
nucleotide polymorphism microarray to two separate patient cohorts, the investigators
successfully identified specific combinations of germline polymorphisms significantly associated with
early clinical relapse. These results raise the exciting possibility that besides somatically acquired
alterations, germline genetic background may also exert an important influence on cancer patient
prognosis and outcome. Future 'personalized medicine' strategies for cancer may thus require
incorporating genomic information from both tumor cells and the non-malignant patient genome.
Commentary
Germline variations and human health
A major advancement of genetic research in recent years
has been the explosion of genome-wide association stud-
ies (GWAS) in the literature from different investigators
and laboratories [1]. The completion of the reference
human genome sequence, and its subsequent comparison
across different human sub-populations, has identified
millions of genetic polymorphisms that differ between
different individuals, families, and ethnic groups [2].
With the availability of increasingly affordable chip tech-
nologies for interrogating these polymorphisms en masse
in individual genomes, it is now possible to consider
identifying, on a comprehensive genome-wide scale, all
genes and genetic variants associated with human disease.
In the area of cancer, GWAS studies have been performed
for multiple different tumor types including breast, lung,
and stomach cancers [3-5]. These studies have both recon-
firmed previously known disease genes (eg FGFR2  in
breast cancer) [3], and also identified novel genetic loci,
such as TNRC9, MAP3K1, and LSP1 for breast cancer [3]
and the nicotinic acetylcholine receptor subunits in lung
cancer [4]. To date, the majority of reported GWAS studies
have employed a case-control design, where affected indi-
viduals with a disease are compared against a matched
population of non-affected normal controls. The genetic
variants identified using such case-control designs thus
represent 'disease susceptibility' loci that can either
increase or decrease an individual's risk to developing dis-
ease. A report published this month in BMC Medicine by
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Van Ness et al. [6] seeks to extend this theme, by asking
whether germline polymorphisms can influence not sim-
ply the onset of disease, but the actual course of disease
prognosis in cancer.
Somatic alterations as dominant drivers of cancer 
progression
The focus of Van Ness et al. on the cancer patient germline
is particularly notable when one considers how the con-
cept of cancer as an acquired somatic disease has domi-
nated the field. In this model, tumor cells are believed to
arise as a consequence of accumulated genetic lesions,
which cause the pathologic activation of oncogenes and
inactivation of key tumor suppressor pathways [7]. Fur-
thermore, multiple studies have already described various
somatically-derived genomic 'signatures' in tumors that
can predict both disease outcome and response to ther-
apy, such as a 70 gene expression signature in breast
tumors that can identify patients with particularly good
prognoses [8], and EGFR mutations in lung cancers that
can predict tumor response to EGFR-targeted therapies
[9,10]. In contrast to the altered cancer genome, studies
analyzing the germline analysis of cancer patients, for the
most part, have been largely confined to the pharmacody-
namic/pharmacokinetic (PK/PD) arena, where patients
are genotyped for polymorphisms in various drug-metab-
olizing genes to identify individuals at greatest risk of
incurring severe drug toxicities (eg UGT1A1 in irinotecan
treatment) [11].
More recently, however, emerging evidence suggests that
in addition to somatic alterations, germline variations
may also play an important role in influencing cancer
prognosis and disease outcome. This might occur if partic-
ular germline variants increase the risk of developing a
particular cancer subtype intrinsically associated with
poor prognosis. For example, in stomach cancer, poly-
morphisms in the PSCA gene have been shown to be asso-
ciated with the development of diffuse-type gastric
adenocarcinoma, a histologic variant traditionally associ-
ated with poor clinical outcome [5]. The influence of host
genetic background on the development of cancers with
differing metastatic traits has also been observed in mouse
models of cancer [12]. Germline polymorphisms could
also influence cancer prognosis by affecting the regulatory
circuitry of cancer cells, by altering promoter-binding sites
for important cancer-related genes such as mdm2, a nega-
tive regulator of p53 [13]. Although such studies are still
relatively few in number, they do suggest that it may be
time to initiate more systematic efforts to understand the
specific role of germline genetic background in determin-
ing the course of cancer progression.
Germline variants may affect outcome in multiple 
myeloma
The report by Van Ness et al. provides promising initial
data that this idea may indeed have scientific merit. This
group has focused on multiple myeloma (MM), a hemat-
opoetic malignancy of plasma B-cells. Although consid-
ered a uniformly fatal disease, individual MM patients are
known to exhibit significant clinical heterogeneity in
terms of disease morphology, time to progression and
response to treatment [14]. To ask whether germline pol-
ymorphisms might underlie some aspect of this clinical
heterogeneity, the investigators designed a customized
single nucleotide polymorphism (SNP) array to measure
genetic polymorphisms across ~1000 genes in biological
pathways relevant to MM or MM therapy, including
immunity and inflammatory pathways, and genes related
to drug metabolism and transport. Although not a
genome-wide approach, the use of a targeted array is not
without its advantages. First, by making use of prior liter-
ature knowledge, the investigators were able to incorpo-
rate many SNPs in pathways and genes relevant for MM
not represented on standard genome-wide SNP arrays.
Second, the use of a smaller SNP set (3500 SNPs) allowed
the study to be performed with relatively smaller numbers
of patient samples while still preserving statistical power,
compared with a typical GWAS study. Third, because the
choice of treatment regimen is an important contributor
to clinical outcome, the use of smaller numbers of patient
samples also facilitates standardization of treatment ther-
apies across independent patient cohorts.
The investigators applied their customized array to two
separate cohorts of MM patients treated with comparable
chemotherapeutic regimens. The recruitment of these
patients was orchestrated through 'Bank on a Cure'
(BOAC), a centralized collection agency for MM patient
material from different corporative groups and institu-
tional trials, established by expert researchers and clini-
cians in the MM field [15]. Using a series of
computational training algorithms, the investigators
showed that they could classify the patients on the basis
of the germline SNP profiles into two distinct groups of
'good prognosis' (>3 year progression-free survival, PFS)
vs 'bad prognosis' (<1 year PFS) groups above random
chance. Although this initial result will undoubtedly
require further validation to assess its ultimate accuracy,
several intriguing trends have already emerged from their
data. Among these, the authors found that accurate classi-
fication was highly dependent on using a multiplex panel
of SNPs rather than any single SNP in isolation, strongly
suggesting that the factors driving disease outcome in MM
are likely to be complex and multifactorial. Another inter-
esting finding was that patient classification accuracy also
increased when the analysis was restricted to non-syno-
mymous SNPs, ie those SNPs causing amino acid differ-BMC Medicine 2008, 6:27 http://www.biomedcentral.com/1741-7015/6/27
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ences in proteins. This may imply that stronger effects on
clinical outcome are likely to be modulated through alter-
ations in protein function, rather than by alterations in
the regulatory pathways controlling the transcription of
these genes.
Challenges for the future
Although obviously exploratory in nature, the promising
results of this initial study have paved the way for more
ambitious and rigorous experimental designs and
projects. Some potential issues with the current study
include the somewhat arbitrary threshold for defining the
prognosis categories, which focuses on extreme cases (<1
year vs >3 years). It would have been interesting, for exam-
ple, to ask if similar SNP associations were also observed
if the analysis was repeated treating patient survival as a
continuous variable. It could also be argued that the lack
of using an unbiased genome-wide approach prohibited
the investigators from discovering potentially novel gene-
disease associations, which might have shed further light
on the regulatory pathways underlying MM. Ultimately,
because this approach is relatively new, the study data will
have to be further scrutinized in several other independ-
ent cohorts to assess the true prognostic power of these
SNPs.
Finally, it will be fascinating to determine whether the
stratification power provided by these germline SNPs
reflects an enhanced propensity of certain patients to
develop a particular poor or good prognosis 'molecular
subtype' of MM, since there is already a significant body
of work describing various somatic alterations in MM that
are predictive of clinical outcome [16,17]. Alternatively, it
is also possible that these survival-associated SNPs may
provide further stratification power beyond that observed
by studying the somatic MM genome alone. In conclu-
sion, this study by Van Ness is quite exciting and likely
represents a model for similar studies in other cancers. It
recognizes that the factors determining disease outcome
in cancer are complex and multifactorial, ranging from
the propensity of a cancer to proliferate and metastasize to
how that cancer might respond to different types of ther-
apy. One possibility for the future might be to test how
such germline information can best be further integrated
with somatic genomics to derive a holistic model for pre-
dicting outcome (Figure 1). Such information might
directly translate to the development of new pharmaceu-
tics, and diagnostic panels for personalized and predictive
medicine.
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